Markers of thrombotic disease: Procoagulant microparticles;Marqueurs des pathologies thrombotiques: Les microparticules procoagulantes

Annales Pharmaceutiques Francaises

Volumn 65, Issue 2, 2007, Pages 75-84

  Morel, O ^b   Toti, F ^b   Freyssinet, J M ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b NONE

Author keywords

Apoptosis; Inflammation; Microparticles; Thrombotic risk; Vascular compartment

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMINOPHOSPHOLIPID; ASCORBIC ACID; BEZAFIBRATE; CARVEDILOL; CILOSTAZOL; CLOPIDOGREL; DIGOXIN; DROTRECOGIN; EFONIDIPINE; ENZYME; ICOSAPENTAENOIC ACID; INFLIXIMAB; LOSARTAN; PHOSPHATIDYLSERINE; SIMVASTATIN; TICLOPIDINE;

ANGIOGENESIS; APOPTOSIS; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL TONE; CELL ACTIVATION; CELL DAMAGE; DEVELOPED COUNTRY; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOSTASIS; INCIDENCE; INFLAMMATION; MORBIDITY; MORTALITY; RISK; THROMBOSIS; VALIDATION STUDY; VEIN THROMBOSIS;

EID: 33947392080     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(07)90020-6     Document Type: Article

References (71)

1. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 (suppl IV): IV-6-IV-19.
2. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
3. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
4. Khot UN, Khot MB, Bajzer CT et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290: 898-904.
5. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1: 1655-62.
6. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology 2005 ; 20 : 22-7.
7. Freyssinet JM, Toti F, Hugel B et al. Apoptosis in vascular disease. Thromb Haemost 1999 ; 82 : 727-35.
8. Morel O, Toti F, Hugel B, Freyssinet JM. Cellular microparticles: A disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-64.
9. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109: 175-80.
10. Abid Hussein MN, Meesters EW, Osmanovic N, Romijn FP, Nieuwland R, Sturk A. Antigenic characterization of endothelial cell-derived microparticles and their detection ex vivo. J Thromb Haemost 2003; 1: 2434-43.
11. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH. Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005; 105: 1515-22.
12. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996; 87: 1409-15.
13. Hrachovinova I, Cambien B, Hafezi-Moghadam A et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 2003; 9: 1020-5.
14. Jy W, Horstmann LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-45.
15. Hugel B, Socie G, Vu T et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999; 93: 3451-6.
16. Morel O, Jesel L, Chauvin M, Freyssinet JM, Toti F. Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost 2003; 1: 2685-7.
17. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59: 277-87.
18. Morel O, Ohlmann P, Morel N et al. Microparticules et pathologies cardiovasculaires. Perspectives thérapeutiques. Arch Mal Coeur Vaiss 2005; 98: 236-41.
19. Muller I, Klocke A, Alex M et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. Faseb J 2003; 17: 476-8.
20. Biro E, Sturk-Maquelin KN, Vogel GMT et al. Human-cell derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 2003; 1: 2561-8.
21. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
22. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-9.
23. Brodsky SV, Malinowski K, Golightly M, Jesty J, Goligorsky MS. Plasminogen activator inhibitor-1 promotes formation of endothelial microparticles with procoagulant potential. Circulation 2002; 106: 2372-8.
24. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 2002; 160: 673-80.
25. Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol 2004; 124: 376-84.
26. Martin S, Tesse A, Hugel B, et al. Shed membranes particles from T lymphocytes impair endothelial function and regulate endothelial gene expression. Circulation 2004; 109: 1653-9.
27. Janiszewski M, Do Carmo AO, Pedro MA, Silva E, Knobel E, Laurindo FR. Platelet-derived exosomes of septic individuals possess proapototic NAD(P)H oxidase activity: a novel vascular redox pathway. Crit Care Med 2004; 32: 818-25.
28. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004; 286: H1910-5.
29. Boulanger CM, Scoazec A, Ebrahimian T et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-52.
30. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 2005; 288: H1004-9.
31. Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, Dignat-George F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood 2002; 99: 3962-70.
32. Morel O, Hugel B, Jesel L et al. Microparticules membranaires procoagulantes et complications athérothrombotiques chez le patient diabétique. Arch Mal Coeur Vaiss 2004 ; 97 : 1006-12.
33. Sabatier F, Darmon P, Hugel B et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51: 2840-5.
34. Ferreira AC, Peter AA, Mendez AJ et al. Postprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation 2004; 110: 3599-603.
35. Day SM, Reeve JL, Pedersen B et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-8.
36. Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 2004; 104: 3190-7.
37. Falati S, Liu Q, Gross P et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.
38. Furie B, Furie BC. Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 2004; 10: 171-8.
39. Myers DD, Hawley AE, Farris DM et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38: 1075-89.
40. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003; 188: 1618-29.
41. Aras O, Shet A, Bach RR et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 2004; 103: 4545-53.
42. Nieuwland R, Berckmans RJ, McGregor S et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-5.
43. Gando S, Kameue T, Matsuda N et al. Combined activation of coagulation and inflammation has an important role in multiple organ dysfunction and poor outcome after severe trauma. Thromb Haemost 2002; 88: 943-9.
44. Gando S, Kameue T, Matsuda N et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003; 109: 119-24.
45. Gando S, Kameue T, Matsuda N, Sawamura A, Hayakawa M, Kato H. Systemic inflammation and disseminated intravascular coagulation in early stage of ALI and ARDS: role of neutrophil and endothelial activation. Inflammation 2004; 28: 237-44.
46. Gando S, Kameue T, Morimoto Y, Matsuda N, Hayakawa M, Kemmotsu O. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care 2002; 30: 1729-34.
47. Mallat Z, Benamer H, Hugel B et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
48. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004; 91: 146-54.
49. Vidal C, Spaulding C, Picard F et al. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost 2001; 86: 784-90.
50. Bernal-Mizrachi L, Jy W, Jimenez JJ et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-70.
51. Morel O, Hugel B, Jesel L et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 2: 1118-26.
52. Morel O, Hugel B, Jesel L et al. Sustained generation of procoagulant microparticles after acute myocardial infarction in diabetes mellitus: role of endothelial damage and platelet activation. Thromb Haemost 2004; 91: 345-53.
53. Bernal-Mizrachi L, Jy W, Fierro C et al. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol 2004; 97: 439-46.
54. Goto S, Tamura N, Li M et al. Differents effects of various anti-GPIIb-IIIa agents on shear induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 1: 2022-30.
55. Proulle V, Hugel B, Guillet B et al. Injection of recombinant activated factor VII can induce transient increase in circulating procoagulant microparticles. Thromb Haemost 2004; 91: 873-8.
56. Heloire F, Weill B, Weber S, Batteux F. Aggregates of endothelial microparticles and platelets circulate in peripheral blood. Variations during stable coronary disease and acute myocardial infarction. Thromb Res 2003; 110: 173-80.
57. Morel O, Jesel L, Hugel B et al. Protective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost 2003; 1: 171-7.
58. Inami N, Nomura S, Kikuchi H et al. P-selectin and platelet-derived microparticles associated with monocyte activation markers in patients with pulmonary embolism. Clin Appl Thromb Hemost 2003; 9: 309-16.
59. Shouzu A, Nomura S, Omoto S, Hayakawa T, Nishikawa M, Iwasaka T. Effect of Ticlopidine on Monocyte-derived Microparticles and Activated Platelet Markers in Diabetes Mellitus. Clin Appl Thromb Hemost 2004; 10: 167-73.
60. Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S. Effect of ticlopidine on platelet-derived microparticles in patients with connective tissue diseases. Haemostasis 1999; 29: 255-61.
61. Nomura S, Shouzu A, Omoto S et al. Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998; 80: 388-92.
62. Nomura S, Imamura A, Okuno M et al. Platelet-derived microparticles in patients with arteriosclerosis obliterans: enhancement of high shear-induced microparticle generation by cytokines. Thromb Res 2000; 98: 257-68.
63. Serebruany VL, Malinin AI, Jerome SD et al. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003; 146: 713-20.
64. Rossig L, Hoffmann J, Hugel B et al. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation 2001 ; 104 : 2182-7.
65. Nomura S, Kanazawa S, Fukuhara S. Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus. J Diabetes Complications 2003; 17: 153-9.
66. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004; 10: 133-41.
67. Kagawa H, Nomura S, Nagahama M, Ozaki Y, Fukuhara S. Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin Appl Thromb Hemost 2001; 7: 153-7.
68. Rossig L, Haendeler J, Mallat Z et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol 2000; 36: 2081-9.
69. Nomura S, Kanazawa S, Fukuhara S. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens 2002; 16: 539-47.
70. Chirinos JA, Castrellon A, Zambrano JP et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart rythm 2005; 2: 525-9.
71. Chamouard P, Desprez D, Hugel B et al. Circulating cell derived microparticles in crohn's disease. Diminution after treatment with infliximab. Dig Dis Sci 2005; 50: 574-80.